Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors
March 04 2021 - 4:01PM
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases, today announced the appointment of
Andrew Sinclair, Ph.D., to its board of directors. Dr. Sinclair
will replace Erez Chimovits, who will step down from the Board of
Directors.
“Abingworth was a significant investor in our recent successful
$152 million financing and we are extremely pleased to welcome
Andrew, a highly-respected healthcare investor, to our Board of
Directors,” said Chen Schor, President and Chief Executive Officer
of Adicet Bio, Inc. “Andrew’s significant life science experience
amassed throughout his career, both from the financial and
scientific perspective, will be tremendously valuable to Adicet as
we continue to advance ADI-001 into the clinic and expand our
pipeline of ‘off-the-shelf’ gamma delta T cell product candidates.
In addition, we would like to thank Erez for his five years of
service and significant contributions to Adicet which have played
an important role in advancing our strategic priorities.”
“I am excited to join Adicet Bio’s Board of Directors,” said
Andrew Sinclair. “Adicet’s allogeneic gamma delta T
cell approach has a number of potential advantages over other cell
therapy platforms and I look forward to working with my fellow
board members and company management to advance Adicet’s corporate
goals in the years ahead.”
Dr. Sinclair is currently a partner and portfolio manager at
Abingworth LLP, a life sciences investment group. He has been at
Abingworth since 2008 where he has served in various positions
focusing on investments in public and private biotech and
pharmaceutical companies. Dr. Sinclair currently serves on the
boards of directors of Soleno Therapeutics, Inc., Sierra Oncology
and Verona Pharma plc. Prior to joining Abingworth, he was senior
equity analyst, director, at HSBC Global Markets, where he was
responsible for investment research in the mid-cap pharmaceutical
sector. Previously, Andrew held biotechnology analyst positions at
Credit Suisse and SG Cowen. Dr. Sinclair received his B.Sc. in
Microbiology from King's College London and his Ph.D. in Chemistry
and Genetic Engineering at the BBSRC Institute of Plant Science,
Norwich. Andrew qualified as a chartered accountant with KPMG.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer and
other diseases. Adicet is advancing a pipeline of “off-the-shelf”
gamma delta T cells, engineered with chimeric antigen receptors and
T cell receptor-like antibodies to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in patients.
For more information, please visit our website at
http://www.adicetbio.com.
About Abingworth
Abingworth is a leading transatlantic life sciences investment
firm. Abingworth helps transform cutting-edge science into novel
medicines by providing capital and expertise to top calibre
management teams building world-class companies. Since 1973,
Abingworth has invested in 172 life science companies, leading to
44 M&As and 69 IPOs. Our therapeutic focused investments fall
into three categories: seed and early-stage, development stage, and
clinical co-development. Abingworth supports its portfolio
companies with a team of experienced professionals at offices in
London, Menlo Park (California), and Boston.
Forward-Looking Statements
This press release contains “forward-looking statements” of
Adicet within the meaning of the Private Securities Litigation
Reform Act of 1995 relating to business and operations of Adicet
including, but not limited to preclinical and clinical development
of Adicet’s product candidates, including future plans or
expectations for ADI-001 and potential therapeutic effects of
ADI-001, the timing and outcome of discussions with FDA and other
regulatory agencies, expectations regarding the design,
implementation, timing, and success of its future clinical studies
of ADI-001, and our growth as a company and the anticipated
contribution of the members of our board of directors to our
operations and progress. The words “may,” “will,” “could,” “would,”
“should,” “expect,” “plan,” “anticipate,” “intend,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements,
including without limitation, Adicet’s ability to execute on its
strategy; that positive results from a clinical study may not
necessarily be predictive of the results of future or ongoing
clinical studies; the expected impact and contribution of our board
of directors and executives to our business as well as those risks
and uncertainties set forth in the company’s most recent quarterly
report on Form 10-Q and subsequent filings with the Securities and
Exchange Commission. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Adicet’s actual results to differ from those contained in the
forward-looking statements, see the section entitled “Risk Factors”
in Adicet’s most recent annual report on Form 10-K and our periodic
reports on Form 10-Q and Form 8-K filed with the SEC, as well as
discussions of potential risks, uncertainties, and other important
factors in Adicet’s other filings with the SEC. All information in
this press release is as of the date of the release, and Adicet
undertakes no duty to update this information unless required by
law.
Adicet Bio, Inc.Investor and Media
Contacts
Anne Bowdidgeabowdidge@adicetbio.com
Janhavi MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Apr 2023 to Apr 2024